Prince J. Kannankeril

Prince J. Kannankeril

Auto-generated profile, based on publicly available information

Prince J. Kannankeril

Department of Pediatrics (P.J.K.), Monroe Carell Jr. Children’s Hospital at Vanderbilt, Vanderbilt University Medical Center, Nashville, TN

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2007 in Current Opinion in Cardiology
Verified
Journal Article
Closed access
PKPrince J Kannankeril
Prince J Kannankeril
DRDan M Roden
Dan M Roden
A wide array of drugs can cause marked QT prolongation with the associated risk of torsade de pointes. The large number of drugs with this potential, the correspondingly large number of patients exposed to such drugs, and the potentially fatal outcome make drug-induced long QT syndrome an important public health problem. This review focuses on mechanisms underlying QT prolongation and proarrhythmia, risk factors, including the role of genetic variants, and the unifying framework of reduced repolarization reserve. While most drugs that prolong the QT block a specific potassium channel, novel mechanisms altering protein trafficking have been discovered. The progression to torsade de pointes may be less related to degree of QT prolongation than to drug effects on transmural dispersion or variability of repolarization. Our understanding of certain predisposing risk factors has been further refined. Ongoing research continues to elucidate the mechanisms underlying drug-induced long QT syndrome. Importantly, studies are establishing improved predictors of risk for progression to torsade de pointes, in addition to the degree of QT prolongation, which is an imperfect predictor. Nonetheless, drug-induced long QT syndrome and torsade de pointes pose unique challenges for clinicians, researchers, drug-development programs, and regulatory agencies.

1 July 2017 in JAMA Cardiology
Verified
Journal Article
Open access
PDF file
PKPrince J. Kannankeril
Prince J. Kannankeril
JMJeremy P. Moore
Jeremy P. Moore
MCMarina Cerrone
Marina Cerrone
SPSilvia G. Priori
Silvia G. Priori
NKNaomi J. Kertesz
Naomi J. Kertesz
BKBjorn C. Knollmann
Bjorn C. Knollmann
Catecholaminergic polymorphic ventricular tachycardia (CPVT), a rare genetic arrhythmia syndrome, is characterized by polymorphic ventricular tachycardia with physical or emotional stress in patients with a structurally normal heart.1 It can be a particularly lethal channelopathy, resulting in symptom onset during childhood and cardiac arrest as a frequent presentation.2 Mutations in the genes encoding the cardiac ryanodine receptor 2 calcium release channel (RYR2 [OMIM 180902]) or cardiac calsequestrin (CASQ2 [OMIM 114251]) are implicated in approximately 60% of cases.3,4 These proteins regulate intracellular calcium homeostasis in myocytes, and disruptions resulting in excessive sarcoplasmic reticulum calcium release are arrhythmogenic.5 The recommended first-line therapy for CPVT consists of β-blockers,6 but recurrent events are common despite β-blocker therapy, especially in children, and rates of near-fatal and fatal events remain unacceptably high.7 The implantable cardioverter defibrillator (ICD) can be useful in patients at high risk of CPVT events, but ICD shocks can trigger catecholamine release, resulting in arrhythmic storm, multiple shocks, and death.8,9 Left cardiac sympathetic denervation is a promising option for severely affected patients with syncope despite optimal medical therapy, but it is limited to specialized centers.10,11 To date, randomized clinical trials have not been performed in CPVT and are exceptional in cardiac channelopathy research, as stated in the most recent international expert consensus statement: “randomized and/or blinded studies do not exist in this field”.6(p1193)

30 May 2019 in European Heart Journal
Verified
Journal Article
Closed access
CWChristian van der Werf
Christian van der Werf
KLKrystien V Lieve
Krystien V Lieve
JBJ Martijn Bos
J Martijn Bos
CLConor M Lane
Conor M Lane
IDIsabelle Denjoy
Isabelle Denjoy
AWArthur A Wilde
Arthur A Wilde
Aims: In patients with catecholaminergic polymorphic ventricular tachycardia (CPVT), implantable cardioverter-defibrillator (ICD) shocks are sometimes ineffective and may even trigger fatal electrical storms. We assessed the efficacy and complications of ICDs placed in patients with CPVT who presented with a sentinel event of sudden cardiac arrest (SCA) while undiagnosed and therefore untreated. Methods and results: We analysed 136 patients who presented with SCA and in whom CPVT was diagnosed subsequently, leading to the initiation of guideline-directed therapy, including β-blockers, flecainide, and/or left cardiac sympathetic denervation. An ICD was implanted in 79 patients (58.1%). The primary outcome of the study was sudden cardiac death (SCD). The secondary outcomes were composite outcomes of SCD, SCA, appropriate ICD shocks, and syncope. After a median follow-up of 4.8 years, SCD had occurred in three patients (3.8%) with an ICD and none of the patients without an ICD (P = 0.1). SCD, SCA, or appropriate ICD shocks occurred in 37 patients (46.8%) with an ICD and 9 patients (15.8%) without an ICD (P < 0.0001). Inappropriate ICD shocks occurred in 19 patients (24.7%) and other device-related complications in 22 patients (28.9%). Conclusion: In previously undiagnosed patients with CPVT who presented with SCA, an ICD was not associated with improved survival. Instead, the ICD was associated with both a high rate of appropriate ICD shocks and inappropriate ICD shocks along with other device-related complications. Strict adherence to guideline-directed therapy without an ICD may provide adequate protection in these patients without all the potential disadvantages of an ICD.

27 April 2020 in The Journal of Physiology
Verified
Journal Article
Open access
PDF file
MWMatthew J. Wleklinski
Matthew J. Wleklinski
PKPrince J. Kannankeril
Prince J. Kannankeril
BKBjӧrn C. Knollmann
Bjӧrn C. Knollmann
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a stress‐induced cardiac channelopathy that has a high mortality in untreated patients. Our understanding has grown tremendously since CPVT was first described as a clinical syndrome in 1995. It is now established that the deadly arrhythmias are caused by unregulated ‘pathological’ calcium release from the sarcoplasmic reticulum (SR), the major calcium storage organelle in striated muscle. Important questions remain regarding the molecular mechanisms that are responsible for the pathological calcium release, regarding the tissue origin of the arrhythmic beats that initiate ventricular tachycardia, and regarding optimal therapeutic approaches. At present, mutations in six genes involved in SR calcium release have been identified as the genetic cause of CPVT: RYR2 (encoding ryanodine receptor calcium release channel), CASQ2 (encoding cardiac calsequestrin), TRDN (encoding triadin), CALM1, CALM2 and CALM3 (encoding identical calmodulin protein). Here, we review each CPVT subtype and how CPVT mutations alter protein function, RyR2 calcium release channel regulation, and cellular calcium handling. We then discuss research and hypotheses surrounding the tissue mechanisms underlying CPVT, such as the pathophysiological role of sinus node dysfunction in CPVT, and whether the arrhythmogenic beats originate from the conduction system or the ventricular working myocardium. Finally, we review the treatments that are available for patients with CPVT, their efficacy, and how therapy could be improved in the future. image

1 February 2005 in Heart Rhythm
Verified
Journal Article
Closed access
PKPrince J. Kannankeril
Prince J. Kannankeril
DRDan M. Roden
Dan M. Roden
KNKris J. Norris
Kris J. Norris
SWS.PAtrick Whalen
S.PAtrick Whalen
AGAlfred L. George
Alfred L. George
KMKatherine T. Murray
Katherine T. Murray

1 February 2022 in Circulation
Verified
Journal Article
Closed access
PDF file
PPPuck J. Peltenburg
Puck J. Peltenburg
DKDania Kallas
Dania Kallas
JBJohan M. Bos
Johan M. Bos
KLKrystien V. V. Lieve
Krystien V. V. Lieve
SFSonia Franciosi
Sonia Franciosi
AWArthur A.M. Wilde
Arthur A.M. Wilde
Background: Symptomatic children with catecholaminergic polymorphic ventricular tachycardia (CPVT) are at risk for recurrent arrhythmic events. β-Blockers decrease this risk, but studies comparing individual β-blockers in sizeable cohorts are lacking. We aimed to assess the association between risk for arrhythmic events and type of β-blocker in a large cohort of symptomatic children with CPVT. Methods: From 2 international registries of patients with CPVT, RYR2 variant–carrying symptomatic children (defined as syncope or sudden cardiac arrest before β-blocker initiation and age at start of β-blocker therapy <18 years), treated with a β-blocker were included. Cox regression analyses with time-dependent covariates for β-blockers and potential confounders were used to assess the hazard ratio (HR). The primary outcome was the first occurrence of sudden cardiac death, sudden cardiac arrest, appropriate implantable cardioverter-defibrillator shock, or syncope. The secondary outcome was the first occurrence of any of the primary outcomes except syncope. Results: We included 329 patients (median age at diagnosis, 12 [interquartile range, 7–15] years, 35% females). Ninety-nine (30.1%) patients experienced the primary outcome and 74 (22.5%) experienced the secondary outcome during a median follow-up of 6.7 (interquartile range, 2.8–12.5) years. Two-hundred sixteen patients (66.0%) used a nonselective β-blocker (predominantly nadolol [n=140] or propranolol [n=70]) and 111 (33.7%) used a β1-selective β-blocker (predominantly atenolol [n=51], metoprolol [n=33], or bisoprolol [n=19]) as initial β-blocker. Baseline characteristics did not differ. The HRs for both the primary and secondary outcomes were higher for β1-selective compared with nonselective β-blockers (HR, 2.04 [95% CI, 1.31–3.17]; and HR, 1.99 [95% CI, 1.20–3.30], respectively). When assessed separately, the HR for the primary outcome was higher for atenolol (HR, 2.68 [95% CI, 1.44–4.99]), bisoprolol (HR, 3.24 [95% CI, 1.47–7.18]), and metoprolol (HR, 2.18 [95% CI, 1.08–4.40]) compared with nadolol, but did not differ from propranolol. The HR of the secondary outcome was only higher in atenolol compared with nadolol (HR, 2.68 [95% CI, 1.30–5.55]). Conclusions: β1-selective β-blockers were associated with a significantly higher risk for arrhythmic events in symptomatic children with CPVT compared with nonselective β-blockers, specifically nadolol. Nadolol, or propranolol if nadolol is unavailable, should be the preferred β-blocker for treating symptomatic children with CPVT.